Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293697 | 1.00 | LIPE (0.50) | LIPEPDCD1CD274MEN1AHR | |
| SCHEMBL30836715 | 0.90 | LIPE (0.50) | LIPEPDCD1CD274MEN1AHR | |
| SCHEMBL20293126 | 0.90 | LIPE (0.50) | LIPEPDCD1CD274MEN1AHR | |
| SCHEMBL20293076 | 0.89 | LIPE (0.52) | LIPEMEN1AHRKMT2ANPC1 | |
| SCHEMBL31108221 | 0.85 | LIPE (0.41) | LIPEPDCD1CD274 | |
| SCHEMBL31108271 | 0.84 | LIPE (0.52) | LIPEPDCD1CD274MEN1AHR | |
| SCHEMBL31108218 | 0.81 | PDCD1 (0.50) | LIPEPDCD1CD274 | |
| SCHEMBL30836769 | 0.81 | LIPE (0.50) | LIPEPDCD1CD274NPC1RAB9A | |
| SCHEMBL30836800 | 0.79 | MEN1 (0.43) | PDCD1CD274MEN1AHRKMT2A | |
| SCHEMBL21622909 | 0.78 | PDCD1 (0.49) | LIPEPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024214088-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024069448-A1 | SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-04-04 | — | — | WO | disclosed |